Novo Nordisk's CagriSema linked to 25% weight loss in women in post hoc trial analysis
Bitget2026/10/20 13:16- Novo Nordisk presented two analyses of its REDEFINE 1 obesity trial at The Menopause Society 2026 Annual Meeting.
- Investigational CagriSema produced significant weight loss versus placebo in women across menopausal stages, with reductions in waist circumference.
- Gastrointestinal side effects were mostly transient and mild to moderate; treatment discontinuations were more common with CagriSema than placebo.
- The once-weekly treatment combines semaglutide with cagrilintide. A U.S. application was filed in December 2025, with a decision expected in Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SoftBank develops contingency plans for slowdown in US data center business, considers shifting to other countries
A new twist has emerged in the US AI data center investment boom. SoftBank is preparing for cooling US demand and a deteriorating political environment, and does not rule out shifting data center construction priorities to other countries. As cross-border computing power delivery capability improves and investment returns come under question, the logic behind AI infrastructure expansion is loosening, and over $3.5 trillion in infrastructure investment now faces potential impairment risks.
Quantumrail Cancels 10 Billion Won Convertible Bond Offering
Crypto prices
More
